Methotrexate- and/or cytarabine-based chemotherapy may be effective and safe in solid-organ transplant recipients with primary central nervous system lymphomas.
Laura
L
Moise
Clemence
C
Matta
Colette
C
Hanna
Sylvain
S
Pilorge
Christophe
C
Fermé
Antoine
A
Durrbach
Vincent
V
Ribrag
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D016377:Organ Transplantation / Q000379:methods; D012008:Recurrence; D012074:Remission Induction; D014180:Transplantation; D016896:Treatment Outcome
D003561:Cytarabine; D008727:Methotrexate